Review reveals therapeutic potential of CAR-T and CAR-NK cells in systemic sclerosis, indicating prospects for deep immune reset and long-term remission.
Systemic sclerosis (SSc) is a rare, heterogeneous systemic autoimmune rheumatic disease characterized by immune dysregulation, vasculopathy, and excessive fibrosis. SSc is associated with high morbidity and mortality despite current immunosuppressive and anti-fibrotic therapies. Emerging cellular therapies, particularly chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell approaches offer potential for deep immune reset and long-term remission. This review examines the immunobiological rationale for these therapies in SSc and evaluates their early clinical evidence, including comparisons to other autoimmune diseases.
No takes yet. Share an insight, caveat, or question.
Convey et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: